Fig. 1: Long-term treatment of HFD-STZ-Induced T2D mice with rFGF21 improves hyperglycemia, insulin resistance and endothelium-dependent relaxation of aorta. | Cell Death & Disease

Fig. 1: Long-term treatment of HFD-STZ-Induced T2D mice with rFGF21 improves hyperglycemia, insulin resistance and endothelium-dependent relaxation of aorta.

From: Fibroblast growth factor 21 Ameliorates diabetes-induced endothelial dysfunction in mouse aorta via activation of the CaMKK2/AMPKα signaling pathway

Fig. 1

a–e HFD-STZ-induced T2D mice were treated for 33 days with rFGF21 (0.5 mg/kg body weight) or buffer control. a Random fed blood glucose (n = 10). b IPGTT over the course of 120 mins (n = 7–9). c Integrated AUC for changes in blood glucose levels (n = 7–9). d Dose-dependent relaxation of aorta to ACh (n = 5–7). e Phosphorylation level of eNOS in aortas as determined by western blot analysis (upper panel) and quantitation using ImageJ software (lower panel) (n = 3). All data are presented as mean ± SEM. *p < 0.05 vs Control; #p < 0.05 vs T2D

Back to article page